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Aims Increased sympathetic tone in obstructive sleep apnoea results from recurrent episodes of systemic hypoxia and
hypercapnia and might be an important contributor to the development of cardiovascular disease. In this study,
we re-evaluated the role of a speciﬁc population of sympathoexcitatory catecholaminergic C1 neurones of the
rostral ventrolateral medulla oblongata in the control of sympathetic vasomotor tone, arterial blood pressure, and
hypercapnia-evoked sympathetic and cardiovascular responses.
Methods
and results
In anaesthetized rats in vivo and perfused rat working heart brainstem preparations in situ, C1 neurones were acutely
silenced by application of the insect peptide allatostatin following cell-speciﬁc targeting with a lentiviral vector to
express the inhibitory Drosophila allatostatin receptor. In anaesthetized rats with denervated peripheral chemorecep-
tors, acute inhibition of 50% of the C1 neuronal population resulted in  50% reduction in renal sympathetic nerve
activity and a profound fall in arterial blood pressure (by  25 mmHg). However, under these conditions systemic
hypercapnia still evoked vigorous sympathetic activation and the slopes of the CO2-evoked sympathoexcitatory
and cardiovascular responses were not affected by inhibition of C1 neurones. Inhibition of C1 neurones in situ
resulted in a reversible fall in perfusion pressure and the amplitude of respiratory-related bursts of thoracic sympath-
etic nerve activity.
Conclusion These data conﬁrm a fundamental physiological role of medullary catecholaminergic C1 neurones in maintaining
resting sympathetic vasomotor tone and arterial blood pressure. However, C1 neurones do not appear to
mediate sympathoexcitation evoked by central actions of CO2.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
Keywords Sympathetic † Arterial blood pressure † Obstructive sleep apnoea † Hypercapnia † Lentivirus
1. Introduction
Obstructive sleep apnoea is a major public health problem affecting
 5% of the world’s population.
1 Obstructive sleep apnoea often
has no clear manifestations and remains undiagnosed until daytime
somnolence and cognitive problems become evident. Repetitive and
prolonged obstructions of the airways during sleep result in recurrent
periods of hypoxia (decrease in arterial PO2), hypercapnia (increase in
arterial PCO2) and arousal leading to increased sympathetic tone,
endothelial damage and dysfunction.
2,3 These changes may lead
to cardiovascular pathology, including hypertension,
4,5 coronary
artery disease,
6 and cerebrovascular disease.
7,8 Understanding the
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detailed knowledge of the central and peripheral mechanisms under-
lying sympathetic control at rest and during hypoxia and hypercapnia.
Sympathetic vasomotor and cardiac neural activities are produced
by the sympathetic preganglionic neurones in the spinal cord which
receive tonic excitatory drive from supraspinal regions within the
brainstem and the hypothalamus.
9–14 These regions include the
rostral ventrolateral medulla (RVLM), rostral ventromedial and
midline medulla, the A5 cell group of the pons and the paraventricular
hypothalamic nucleus.
9,15 The RVLM is believed to contribute signiﬁ-
cantly to the generation of sympathetic vasomotor tone
9–11,13,14
since in anaesthetized experimental animals acute bilateral inactivation
or ablation of the RVLM neurones leads to a fall in arterial pressure
and sympathetic activity to the levels observed after transection of
the spinal cord or during ganglionic blockade.
9,16,17 Sympathoexcita-
tory RVLM neurones are composed of two groups: a subgroup of
the C1 catecholaminergic neurones (they contain enzymes necessary
to produce adrenaline) and non-catecholaminergic, presumably gluta-
matergic neurons.
10,11,13,17–19
Increases in the level of arterial PCO2 are known to evoke robust
increases in sympathetic activity,
20 but the mechanisms by which this
occurs are not entirely clear. RVLM neurones, including C1 cells, are
spontaneously active and show increased activity during hypercapnia
in vivo.
21 C1 neurones, however, do not appear to be intrinsically che-
mosensitive showing no responses to changes in pH (which follow
changes in PCO2) when studied in vitro.
22,23 Previous studies have
demonstrated that permanent depletion of catecholaminergic C1
neurones (.75%) abolishes sympathoexcitation induced by activation
of peripheral chemoreceptors.
24 However, the contribution of C1
neurones to the increases in sympathetic activity evoked by central
actions of CO2 has not been characterized.
In this study, we targeted C1 neurones with a lentiviral construct to
express Drosophila allatostatin receptor (AlstR).
25 Activation of AlstR
by allatostatin peptide opens G-protein-coupled inward-rectifying
potassium channels, resulting in a strong and reversible neuronal
hyperpolarization.
26–28 Naturally, allatostatin receptors are only
expressed in insects and allatostatin itself does not have apparent bio-
logical activity in mammals.
25,27 Given a signiﬁcant cellular expression
of AlstR is achieved, application of allatostatin can be used for immedi-
ate and reversible inhibition of targeted CNS neurones.
Here, we used this approach to acutely inhibit C1 neurones both
in vivo (in anaesthetized and artiﬁcially ventilated adult rats with dener-
vated peripheral chemoreceptors) and in situ (in arterially perfused
brainstem preparations) to determine the contribution of this neur-
onal population to the generation of resting sympathetic activity.
The role of the C1 group in the development of sympathoexcitatory
responses to systemic hypercapnia was also determined in the in vivo
experiments.
2. Methods
All the experiments were performed in accordance with the European
Commission Directive 86/609/EEC (European Convention for the Protec-
tion of Vertebrate Animals used for Experimental and Other Scientiﬁc
Purposes), the UK Home Ofﬁce (Scientiﬁc Procedures) Act (1986), or
the National Health and Medical Research Council of Australia ‘Guidelines
to promote the wellbeing of animals used for scientiﬁc purposes’ with
project approval from the University College London, University of
Bristol and University of Melbourne Institutional Animal Ethics
Committees.
2.1 Viral vectors
Catecholaminergic brainstem neurones characteristically express tran-
scriptional factor Phox2 and, therefore, can be targeted using viral
vectors to express the gene of interest under the control of an artiﬁcial
promoter PRSx8—Phox2-activated promoter.
29–31 The lentiviral vector
(LVV) system used here was HIV-1-derived and pseudo-typed with the
VSV-G envelope.
32 The plasmid pTYF-PRSx8-AlstR-IRES2-EGFP was
cloned into the LVV. Titres of PRSx8-AlstR-EGFP-LV and the control
virus (PRSx8-EGFP-LV) were between 1 × 10
9 and 1 × 10
10 pfu. Viral
concentration and titration were performed as described in detail
previously.
32
2.2 In vivo gene transfer
Post-weaned male Sprague Dawley or Wistar rats (50–80 g) were anaes-
thetized with a mixture of ketamine (60 mg kg
21; i.m.) and medetomidine
(250 mgk g
21, i.m.). Animals were placed in a stereotaxic frame and two
microinjections per side of PRSx8-AlstR-EGFP-LV or PRSx8-EGFP-LV
(0.25 mL each) were delivered into the rostral ventrolateral reticular for-
mation of the medulla oblongata. The microinjection pipette was angled
and positioned + 1.7 mm lateral from the midline. The exact RVLM coor-
dinates (adapted to our stereotaxic apparatus) in these young rats were
determined in dedicated preliminary trials using microinjections of ﬂuor-
escent beads with subsequent histological analysis to verify the sites of
delivery. Anaesthesia was reversed with atipemazole (1 mg kg
21).
2.3 In vivo experiments
Five to six weeks after the injections, Sprague Dawley rats were anaesthe-
tized with urethane (1.15 g kg
21 i.v., supplemented with 5–10 mg i.v. as
required) following femoral vein cannulation under isoﬂurane (3%) induc-
tion (experiments conducted at the University College London). The
depth of anaesthesia was monitored using the stability of blood pressure,
heart rate, and lack of ﬂexor responses to a paw-pinch. The femoral artery
was cannulated for recordings of the arterial blood pressure. Body temp-
erature was kept constant at 37.0+0.28C. The trachea was cannulated
and the animal was ventilated artiﬁcially (frequency 1 Hz, volume 2–
2.5 mL) with O2-enriched air ( 30% O2). The end-tidal level of CO2
was monitored continuously (Capstar-100, CWE, Inc., USA); arterial
PCO2, PO2, and pH were measured regularly. The left renal nerve was dis-
sected retroperitoneally and its activity was recorded using implanted
bipolar silver electrodes. Carotid sinus and aortic nerves were sectioned
to eliminate inputs from the peripheral chemoreceptors and arterial bar-
oreceptors. Effective peripheral chemodenervation was conﬁrmed at the
end of each experiment by monitoring lack of the respiratory response to
a brief bout of systemic hypoxia (lowering O2 in the inspired gas mixture
to 10%).
It has been shown previously that allatostatin is capable of diffusing
deep into the brain tissue reaching neurones of the respiratory rhythm-
generating circuits even after administration into the IV cerebral ventri-
cle.
33 To aid delivery of allatostatin to the transduced C1 neurones
located in the rostroventrolateral aspect of the medullary reticular for-
mation, the ventral surface of the medulla oblongata (VMS) was
exposed as described previously.
34 Artiﬁcial cerebrospinal ﬂuid (aCSF;
saturated with 95% O2/5% CO2, pH 7.4) or allatostatin (10 mMi n
aCSF; Ser-Arg-Pro-Tyr-Ser-Phe-Gly-Leu-NH2, Phoenix Pharmaceuticals,
USA) was applied to the VMS of rats transduced with
PRSx8-AlstR-EGFP-LV (n ¼ 8) or PRSx8-EGFP-LV (n ¼ 3). All the
animals were subjected to the same experimental interventions in the fol-
lowing sequence: the renal sympathetic nerve activity (SNA), blood
pressure, and heart rate responses to increased level of CO2 in inspired
air were ﬁrst determined 5 min after application of aCSF, followed by
two subsequent CO2 challenges, one after at least 30 min recovery
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allatostatin on SNA and cardiovascular variables was assessed at the same
time), and another after allatostatin washout from the VMS by 60 min of
continuous aCSF superfusion (n ¼ 8). Following recovery (at least
60 min), animals were subjected to another CO2 challenge and the
effect of allatostatin on the PRSx8-AlstR-EGFP-LV transduced brainstem
was also tested at the peak of the CO2-evoked sympathoexcitatory
response (n ¼ 8).
A separate experiment was conducted to determine whether the
effects of allatostatin were mediated in part via inhibition of the neigh-
bouring glutamatergic chemosensitive neurones of the retrotrapezoid
nucleus (RTN). Some of the chemosensitive RTN neurones express
Phox2b and may have been transduced also due to spill over of the
PRSx8-AlstR-EGFP-LV from the site of injection. Glutamatergic excitatory
inputs to the RVLM, including these from the RTN were blocked by appli-
cation of ionotropic excitatory amino acid receptor antagonist kynurenic
acid (Kyn, 50 mM) on the VMS. Next, CO2 was added to the inspired gas
mixture, and allatostatin was applied at the peak of the hypercapnic
response as described above.
2.4 In situ experiments
Experiments using in situ perfused working heart brainstem-spinal cord
preparations
35–37 were conducted to complement the data obtained
using in vivo preparations. The main objective was to determine the
effect of allatostatin-evoked inhibition of C1 neurones on SNA in
the absence of anaesthetics. Brieﬂy, 8–10 days after the injections of
the viral vectors, Wistar rats (experiments conducted at the University
of Melbourne) were deeply anaesthetized with isoﬂurane until loss of
paw withdrawal reﬂex, bisected below the diaphragm, exsanguinated,
immersed in cold carbogenated Ringer solution, and decerebrated precol-
licularly. Lungs were removed and the descending aorta was isolated and
cleaned. Preparations were transferred to a recording chamber and a
double lumen cannula was placed into the descending aorta for retrograde
perfusion with a Ringer solution containing in mM: NaCl (125), NaHCO3
(24), KCl (3), CaCl2 (2.5), MgSO4 (1.25), KH2PO4 (1.25), and D-glucose
(10). Ficoll (MWt 20 000; 1.25%) was added as an oncotic agent and
the perfusion solution was saturated with 95% O2-5% CO2 (pH 7.35–
7.4; osmolality 290+5 mosm kg H2O
21 at 318C). Carotid and aortic
bodies inputs were left intact. Neuromuscular blockade was achieved
using vecuronium bromide added to the perfusate (2–4 mgm L
21).
Phrenic nerve (PNA) and thoracic sympathetic nerve (tSNA) activities
were simultaneously recorded. Signals were ampliﬁed (×20k), ﬁltered
(50–1500 Hz), digitized, and recorded using Spike 2 software (CED, Cam-
bridge, UK).
Allatostatin (1 mM) was added to the perfusate for 10–15 min. Fresh
perfusate was used to washout the peptide. Since in vivo experiments
(see Results below) demonstrated that C1 neurones are unlikely to be
responsible for the increases in sympathetic drive evoked by central
actions of CO2, hypercapnia-evoked responses were not re-tested.
2.5 Immunohistochemistry
At the end of the in vivo experiments, animals were perfused transcardially
with 0.9% NaCl solution followed by 500 mL of 4% paraformaldehyde
(PFA). Brainstems were removed, post-ﬁxed for 12 h in 4% PFA at 48C
and cryoprotected in 30% sucrose. Medulla oblongata was sectioned
using a freezing microtome, and a series of coronal sections (30 mm)
was collected and stored in anti-freeze at 2208C for subsequent histo-
logical processing. Sections were immunostained for detection of tyrosine
hydroxylase (TH; marker of catecholaminergic neurones) and EGFP.
Immunohistochemical detection of the latter was necessary for positive
identiﬁcation of the transduced neurones, because in our preliminary
trials we found weak EGFP ﬂuorescence following transduction with
PRSx8-AlstR-EGFP-LV. Tissue was incubated in chicken anti-GFP antibody
(1:250, Ave ´s) for 48 h followed by sheep anti-TH antiserum for 24 h
(1:250, Abcam). Secondary antibodies were goat anti-chicken Alexa 568
(1:1000, Molecular probes) and biotinilated goat anti-sheep (1:500) ampli-
ﬁed by ﬂuorescein avidin DCS (1:250, Vector laboratories).
2.6 Autoradiography
The distribution of transgenic allatostatin receptor expression was exam-
ined using an autoradiography protocol modiﬁed from.
38 The brains were
removed, snap-frozen in iso-pentane cooled on dry ice, and 20 mm
coronal sections were cut using a cryostat at 2208C, mounted on
gelatine-coated slides and desiccated at 48C prior to storage at 2808C.
Sections were incubated for 20 min in a buffer containing 10 mM
HEPES, 5 mM MgCl2, 1 mM phenylmethanesulfonyl ﬂuoride, 1 mM
EGTA, 1 mM O-phenanthroline (pH 7.4) at room temperature followed
by incubation for 1 h in the same buffer containing 10 mg mL
21 BSA
and
125I-allatostatin (90 pM; iodinated by ProSearch International,
Australia). To determine the level of non-speciﬁc binding, some sections
were incubated with 1 mM of unlabelled allatostatin. Sections were
washed, air dried and exposed to X-ray ﬁlm for 3–4 weeks.
125I-radioactivity standards were also included to enable calibration of
binding density. Following exposure, sections on the autoradiographs
were scanned and images were analysed to determine optical densities
of the binding areas using Scion Image Software (Scion Corp, USA).
2.7 Data acquisition and analysis
Renal SNA, blood pressure, and tracheal pressure were recorded using a
Power 1401 interface and Spike2 software. SNA was ampliﬁed (×20 000),
ﬁltered (80–800 Hz), and sampled at a rate of 11 kHz. Physiological data
were digitized and analysed ofﬂine (Spike2). Heart rate was derived from
the blood pressure traces. Rectiﬁed SNA sampled at 100 Hz was
smoothed with a time constant of 10 s to obtain mean level (ML) of
activity. CO2 and allatostatin-evoked changes in RSNA were normalized
with respect to resting activity in normoxia/normocapnia (100%) and
complete the absence of discharges (0%) following administration of the
ganglionic blocker hexamethonium (20 mg; i.v.). The data are expressed
as means+SE and were compared using Student’s paired t-test.
A P-value of less than 0.05 was considered to be signiﬁcant.
In the in situ experiments, tSNA was analysed ofﬂine (Spike2) using cus-
tomized scripts. Rectiﬁed tSNA was smoothed with a time constant of
50 ms and MLs were taken from a 2 min time period. Phrenic triggered
averaging across 20 respiratory cycles was carried out to determine the
amplitude of the respiratory-related bursts of tSNA before and after alla-
tostatin application.
Distribution of EGFP-immunoreactive (EGFP-IR) and TH-IR neurones
was analysed using epiﬂuorescence microscopy. Colocalization of EGFP
with TH was determined by visual inspection through a ×20 objective.
Cell counting was performed manually using a one in three series of
30 mm sections of the brainstem. TH positive cells transduced with
AlstR-EGFP were counted on both sides of the brain regardless of staining
intensity, and cell numbers were summed. Efﬁcacy of the transduction is
expressed as a percentage of TH-IR neurones expressing AlstR-EGFP
locatedintherostralventrolateralreticularformationofthemedullaoblon-
gata  11.3–12.8 mmcaudaltoBregma(Figure1A).Anatomicalreconstruc-
tion of transduced neurones in a representative brainstem was performed
manually using Paxinos and Watson stereotaxic atlas as a guide (Figure 1B).
3. Results
Transduction efﬁcacy was examined in the brainstems of all the
animals by immunohistochemical detection of EGFP and TH
co-localization or by autoradiographic detection of allatostatin recep-
tor binding (Figure 1). EGFP immunostaining revealed bilateral clusters
of AlstR-EGFP-expressing neurones in the rostral ventrolateral reticu-
lar formation of the medulla oblongata (between 11.3 and 12.8 mm
Central sympathetic control 705caudal to Bregma, Figure 1B). EGFP-IR was present both in the soma
and dendritic processes of the transduced TH-positive neurones
(Figure 1A). The distribution of transduced neurones in a representa-
tive brainstem is illustrated in Figure 1B. AlstR-EGFP expression was
found in 51+7% (n ¼ 12) of all identiﬁed TH-positive RVLM neur-
ones, conﬁrming effective targeting of the C1 neuronal population
with PRSx8-AlstR-EGFP-LV. A scatter of EGFP-expressing neurones
showing no immunoreactivity for TH was also found in the ventrolat-
eral reticular formation immediately rostral to the caudal border of
the facial nucleus corresponding to the anatomical location of the
RTN (Figure 1B).
Strong
125I-allatostatin binding was detected bilaterally in all the
animals injected with PRSx8-AlstR-EGFP-LV within the same rostro-
caudal distribution as described above (Figure 1C). No speciﬁc AlstR
binding was observed in the RVLM of naı ¨ve rats, animals injected
with PRSx8-EGFP-LV, or after incubation of the slices with excess
amount (1 mM) of unlabelled allatostatin (data not shown) indicating
high afﬁnity and speciﬁc binding.
In anaesthetized, peripheral chemo- and baro-denervated and arti-
ﬁcially ventilated rats transduced with PRSx8-AlstR-EGFP-LV into the
RVLM (n ¼ 8), application of allatostatin (10 mM) onto the VMS in
normoxia/normocapnia resulted in immediate and profound
reductions in resting RSNA (by 51+5%; P ¼ 0.009; Figure 2), mean
ABP (MABP; by 25.4+3.9 mmHg; P ¼ 0.0003; Figure 2A and C), and
heart rate (by 41+7 b.p.m.; P ¼ 0.0003). Allatostatin (0.01–2 mM)
had no effect on RSNA, MABP, or heart rate in animals transduced
with PRSx8-EGFP-LV (n ¼ 3; Figure 2C) or injected with
PRSx8-AlstR-EGFP-LV rostral to the RVLM ( 9.5 mm from
Bregma) and showing no transgene expression in the C1 region
(n ¼ 5; data not shown). Therefore, allatostatin does not appear to
cross-react with endogenous targets within the rat brainstem presym-
pathetic circuits.
Rising levels of inspired CO2 in rats with denervated peripheral
chemoreceptors (n ¼ 8) induced an increase in RSNA (by 80+
20%; P ¼ 0.002) and MABP (by 23.7+6.6 mmHg; P ¼ 0.004)
(Figure 3). The heart rate was not signiﬁcantly affected during hyper-
capnia (P ¼ 0.206). Similar CO2-evoked increases in RSNA (by
74.6+15%; P ¼ 0.0006) and MABP (by 22.1+6.8 mm Hg; P ¼
0.008) were observed in the presence of allatostatin on the VMS of
transduced rats (Figure 3). However, these responses were
mounted from the lower levels of RSNA and arterial blood pressure
achieved by allatostatin-evoked inhibition of the RVLM circuits
(Figure 3B). Although peak CO2-evoked increases in RSNA and
MABP were signiﬁcantly smaller in comparison with those evoked
during hypercapnia in control conditions (P ¼ 0.004 and P ¼ 0.006,
respectively), the slopes of the responses to CO2 were similar
before and after application of allatostatin on the VMS of rats trans-
duced with PRSx8-AlstR-EGFP-LV (Figure 3B).
Inhibition of the transduced RVLM neurones by allatostatin applied
on the VMS at the peak of the CO2-evoked sympathoexcitatory
response resulted in a signiﬁcant reduction in RSNA (by 72.0+
1.5%; n ¼ 8; P ¼ 0.003), MABP (by 36.3+4.8 mm Hg; n ¼ 8; P ¼
0.0003) and HR (by 26+7 b.p.m.; n ¼ 8; P ¼ 0.0008) (Figure 4). In
conditions of RVLM ionotropic excitatory amino acid receptor block-
ade following application of Kyn (50 mM) on the VMS, hypercapnia
was still effective in triggering increases in RSNA and MABP
(Figure 4C), while subsequent allatostatin application effectively
reduced RSNA by 24+2% (n ¼ 3; P ¼ 0.015) and MABP by 15+
5 mmHg (n ¼ 3; P ¼ 0.025) (Figure 4C).
In the perfused working heart brainstem preparations of rats trans-
duced with PRSx8-AlstR-EGFP-LV into the RVLM (n ¼ 7), addition of
allatostatin (1 mM) to the perfusate caused a signiﬁcant fall in the per-
fusion pressure (by 6.3+1.2 mm Hg; P ¼ 0.003), reduction in the
amplitude of the Hering–Traube pressure waves and
respiratory-related tSNA bursts (by 29%; P ¼ 0.047, Figure 5). The
timing of the post-inspiratory peaks in tSNA was not altered by inhi-
bition of the RVLM circuits (Figure 5B). Allatostatin added to the per-
fusate of rats which had not been injected with a viral vector (n ¼ 3)
or had been injected with PRsx8-EGFP-LV (n ¼ 2) had no effect on
perfusion pressure, HR, or tSNA (data not shown). On wash out of
allatostatin a full recovery in perfusion pressure, amplitude of the
Hering–Taube waves and sympathetic discharge pattern was
observed (Figure 5A).
4. Discussion
In the present study, we used a LVV to express inhibitory Drosophila
allatostatin receptor in a population of the RVLM catecholaminergic
C1 neurones in order to determine the role of these neurones in
Figure 1 Targeting catecholaminergic C1 neurones in the rostral
ventrolateral medulla oblongata (RVLM) with PRSx8-AlstR-EGFP-LV
(A) Confocal images of tyrosine hydroxylase (TH)-positive neurones
(green) expressing AlstR-EGFP (red). Bregma level -12.8 mm. Scale
bar ¼ 50 mm. (B) Distribution of TH-immunoreactive neurones
expressing AlstR-EGFP in one representative rat brainstem 5
weeks after microinjection of PRSx8-AlstR-EGFP-LV into the
RVLM. Each symbol represents three neurones. Numbers indicate
distances from Bregma. 7, facial motor nucleus; py, pyramidal tract.
(C) Binding of
125I-allatostatin in the rat RVLM 9 days after microin-
jection of PRSx8-AlstR-EGFP-LV. Left, Nissl stain; right, autoradiog-
raphy image showing strong AlstR binding in the rostral
ventrolateral reticular formation. NA, nucleus ambiguus.
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heart rate, and CO2-evoked sympathoexcitatory and cardiovascular
responses. Acute inhibition of approximately half of the C1 neuronal
population resulted in a  50% reduction in renal sympathetic activity
and a substantial fall in the arterial blood pressure suggesting that
these neurones are essential for the maintenance of resting sympath-
etic vasomotor tone. The data obtained also suggest that the RVLM
C1 neurones are unlikely to be responsible for the increases in sym-
pathetic drive evoked by central actions of CO2.
The role of C1 neurones in the regulation of sympathetic activity
and arterial blood pressure was addressed previously by Schreihofer
and Guyenet
24 who used anti-dopamine-beta-hydroxylase antibody
conjugated to ribosomal toxin saporin to produce permanent
lesions of the brainstem catecholaminergic neurones, including C1
cell group. This approach was effective in causing loss of .75% of
C1 neurones but also lesions of the other bulbospinal catecholamin-
ergic cell groups. However, resting SNA and blood pressure were
unaffected.
24 These results are in odds with the data obtained in
the present study and indicate that on a longer time-scale other popu-
lations of sympathoexcitatory neurones (e.g. non-catecholaminergic
RVLM bulbospinal neurones, or sympathoexcitatory neurones of
the hypothalamus and other regions of the brainstem) may effectively
Figure 2 Effect of acute inhibition of AlstR-expressing ventrolateral brainstem neurones on sympathetic nerve activity, arterial blood pressure, and
heart rate in vivo.( A) Representative recording illustrating changes in resting heart rate (HR), arterial blood pressure (ABP), renal sympathetic nerve
activity (RSNA) and mean level (ML) of RSNA in response to allatostatin (10 mM) application on the ventral surface of the medulla oblongata (VMS) in
an animal transduced with PRSx8-AlstR-EGFP-LV into the RVLM (anaesthetized and artiﬁcially ventilated rat with denervated carotid and aortic
bodies). HEX, hexamethonium. (B) Expanded records of raw RSNA before and after application of allatostatin on the VMS in an animal from the
example shown in (A). (C) Summary data showing changes in RSNA and mean ABP (MABP) 5 min after allatostatin application on the VMS in
animals transduced with PRSx8-AlstR-EGFP-LV (AlstR) or PRSx8-EGFP-LV (EGFP) (*P , 0.05).
Figure 3 Effect of acute inhibition of AlstR-expressing ventrolateral brainstem neurones on CO2-evoked sympathetic and cardiovascular responses
in vivo.( A) Representative time-condensed recording illustrating changes in HR, ABP, RSNA, and ML of RSNA in response to repeated increases in the
level of inspired CO2 in the absence and presence of allatostatin (10 mM) on the VMS. Rat was transduced with PRSx8-AlstR-EGFP-LV into the RVLM,
anaesthetized, peripherally chemodenervated and artiﬁcially ventilated. ETCO2, end-tidal CO2.( B) Summary data illustrating slopes of the CO2-
evoked increases in RSNA, MABP, and HR in the absence and presence of allatostatin on the VMS in rats transduced with PRSx8-AlstR-EGFP-LV
into the RVLM. Asterisk indicates signiﬁcant differences in RSNA or MABP before and after application of allatostatin in normo- and hypercapnia,
P , 0.05.
Central sympathetic control 707compensate for the gradual but permanent loss of the C1 group.
Recent studies involving direct and speciﬁc stimulation of the geneti-
cally targeted RVLM C1 neurones conﬁrmed that their activation
increases SNA and arterial blood pressure.
31,39
Histological analysis revealed that in our experiments at least 51%
of TH-positive RVLM neurones were transduced, suggesting that len-
tiviral targeting results in a signiﬁcant AlstR-EGFP expression among
catecholaminergic RVLM neurones. The expression of AlstR-binding
sites within the RVLM region was also conﬁrmed by autoradiography.
These observations are in line with the results of recent studies by
other groups which used viral vectors with the same PRSx8 promo-
ter.
31,40 AlstR-EGFP transduced neurones were identiﬁed in the
RVLM regions occupied by C1 population, thus allowing their revers-
ible inhibition by allatostatin application. Indeed, we demonstrated
recently that expression of AlstR mediates immediate silencing of
the transduced brainstem neurones following allatostatin applications
Figure 4 Effect of acute inhibition of AlstR-expressing ventrolateral brainstem neurones on sympathetic nerve activity and arterial blood pressure in
conditions of enhanced sympathetic drive during hypercapnia in vivo.( A) Representative recording illustrating changes in HR, ABP, RSNA and ML, or
RSNA in response to allatostatin (10 mM) applied on the VMS at the peak of the CO2-evoked sympathetic and cardiovascular responses in an animal
transduced with PRSx8-AlstR-EGFP-LV (anaesthetized, peripherally chemodenervated and artiﬁcially ventilated rat). (B) Expanded records of raw
RSNA during hypercapnia before and after application of allatostatin on the VMS in an animal from the example shown in (A). (C) Summary data
showing changes in RSNA and MABP induced by allatostatin application on the VMS in conditions of ionotropic excitatory amino acid receptor block-
ade by kynurenic acid (Kyn, 50 mM) in hypercapnic animals transduced with PRSx8-AlstR-EGFP-LV. Grey boxes depict periods of hypercapnia.
Figure 5 Effect of acute inhibition of AlstR-expressing ventrolateral brainstem neurones on sympathetic nerve activity and perfusion pressure in the
in situ working heart brainstem preparation. (A) Representative raw data illustrating changes in thoracic sympathetic nerve activity (tSNA) and per-
fusion pressure (PP) in response to addition of allatostatin (1 mM) to perfusate in a rat preparation transduced into the RVLM with
PRSx8-AlstR-EGFP-LV. IPNA, integrated phrenic nerve activity. (B) Phrenic-triggered averages of tSNA across 20 respiratory cycles before and
after application of allatostatin. The amplitude, represented in C is taken as the peak to trough of these averages. Note that the timing of the
peak of tSNA is not altered by allatostatin and occurs during post-inspiration (PI). ME, mid-expiration; I, inspiration; LE, late inspiration. (C)
Summary data showing the effect of allatostatin on the PP, HR, and the amplitude of the respiratory-related tSNA bursts (n ¼ 7; *P , 0.05).
N. Marina et al. 708regardless of the prevailing CO2 tension.
28 However, the PRSx8 pro-
moter is also active in the other notable neighbouring neuronal popu-
lation of chemosensitive Phox2b-expressing RTN neurones, believed
to play an important role in the mechanisms underlying CNS respir-
atory chemosensitivity to changes in PCO2/pH.
28,41 Indeed, a scatter
of EGFP-expressing neurones showing no immunoreactivity for TH
was found rostral to the caudal border of the facial nucleus where
RTN neurones reside.
Since some of the RTN neurones were transduced with
AlstR-EGFP and, therefore, inhibited in the presence of allatostatin,
28
the role of this neuronal population in the generation of sympathetic
activity has to be discussed. RTN neurones are glutamatergic
41 and
project to the RVLM.
42,43 Consistent with previous reports,
44,45 our
data showed that blockade of RTN (and other) inputs to the RVLM
presympathetic circuitry following administration of the broad spec-
trum glutamate receptor antagonist kynurenic acid had no effect on
resting sympathetic activity. These data suggest that the C1 neuronal
population does not require excitatory glutamatergic inputs from the
RTN to generate a signiﬁcant level of sympathetic vasomotor tone.
Our experiments demonstrated that in conditions of ionotropic
glutamatergic receptor blockade, inhibition of the RVLM
AlstR-EGFP-expressing neurones by allatostatin application still
resulted in signiﬁcant decreases in RSNA and MABP during hypercap-
nia. In addition, RTN neurones have not been previously implicated in
generating sympathetic activity and the observations of Moreira
et al.
44 imply that even though a substantial proportion of RTN neur-
ones may have been transduced by PRSx8-AlstR-EGFP-LV,
allatostatin-induced effect on sympathetic activity is unlikely to be
related to inhibition of these neurones.
Interestingly, systemic hypercapnia in the absence of the peripheral
chemoreceptor inputs evoked vigorous increases in SNA, however,
the slopes of the CO2-evoked sympathoexcitatory and cardiovascular
responses were not affected following inhibition of C1 neurones (and
transduced RTN neurones for that matter). Although, there is evi-
dence that hypercapnia increases discharges of C1 neurones in
vivo,
21 recent evidence indicates that these neurones are not
pH-chemosensitive when isolated in vitro.
22,23 Together these recent
reports and the data obtained in the present study suggest that
while providing tonic sympathetic drive, RVLM C1 neurones do not
appear to be responsible for increases in SNA evoked by central
actions of CO2. By extension, the major component of the CO2-
evoked sympathetic response must be provided by bulbospinal non-
catecholaminergic RVLM neurones or sympathoexcitatory neurones
located in other parts of the brain (e.g. rostral ventromedial and
midline medulla, the A5 cell group of the pons or the paraventricular
hypothalamic nucleus) and/or spinal pre- or even post-ganglionic
neurones.
In summary, our data conﬁrm a fundamental physiological function
of a distinct population of catecholaminergic C1 neurones of the
RVLM. In contrast to previous observations based on the results
of the experiments involving chronic and permanent lesions, acute
inhibition of AlstR-EGFP-expressing C1 neurones following appli-
cation of allatostatin reveals that this neuronal group contributes
in a signiﬁcant manner to the maintenance of the sympathetic
tone and arterial blood pressure at rest. Although, C1 neurones
do not appear to mediate sympathoexcitation evoked by central
actions of CO2, this study provides important guidance for further
studies of brain mechanisms underlying increases in sympathetic
vasomotor tone, vascular remodelling, and cardiovascular pathology
which accompany disruptions in gas exchange in patients with
obstructive sleep apnoea.
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